The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CUTAQUIG (Octapharma Australia Pty Ltd)
Product name
CUTAQUIG
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
human immunoglobulin g
Registration type
NCE/NBE
Indication
CUTAQUIG (solution for injection) is indicated for replacement therapy in adults and children in:
- Primary immunodeficiency diseases (PID)
- Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.